Ludo Vanopdenbosch

ORCID: 0000-0001-8858-8096
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Multiple Sclerosis Research Studies
  • Peripheral Neuropathies and Disorders
  • Polyomavirus and related diseases
  • Palliative Care and End-of-Life Issues
  • Neurosurgical Procedures and Complications
  • Cerebral Venous Sinus Thrombosis
  • Rheumatoid Arthritis Research and Therapies
  • Amyotrophic Lateral Sclerosis Research
  • Systemic Lupus Erythematosus Research
  • Mitochondrial Function and Pathology
  • Glioma Diagnosis and Treatment
  • Cytokine Signaling Pathways and Interactions
  • Head and Neck Surgical Oncology
  • Retinal and Optic Conditions
  • Neurology and Historical Studies
  • Childhood Cancer Survivors' Quality of Life
  • Botulinum Toxin and Related Neurological Disorders
  • Meningioma and schwannoma management
  • Family Support in Illness
  • Vascular Malformations Diagnosis and Treatment
  • Parkinson's Disease Mechanisms and Treatments
  • Migraine and Headache Studies
  • Electroconvulsive Therapy Studies
  • Empathy and Medical Education
  • thermodynamics and calorimetric analyses

AZ Sint-Jan
2015-2025

The University of Sydney
2024

Palacký University Olomouc
2024

The University of Western Australia
2024

Düsseldorf University Hospital
2024

Inserm
2024

Heinrich Heine University Düsseldorf
2024

Université de Bordeaux
2024

NeuroRx Research (Canada)
2018

Vrije Universiteit Amsterdam
2018

Background Linezolid is an oxazolidinone antibiotic that increasingly used to treat drug-resistant, gram-positive pathogens. The mechanism of action inhibition bacterial protein synthesis. Optic and/or peripheral neuropathy and lactic acidosis are reported side effects, but the underlying pathophysiological has not been unravelled.

10.1086/501356 article EN Clinical Infectious Diseases 2006-03-17
Robert J. Fox Andrew Chan Ralf Gold J. Theodore Phillips Krzysztof Selmaj and 95 more Ih Chang Mark Novas Jitesh Rana Jing L. Marantz Zdeněk Ambler Edvard Ehler Eva Havrdová Eva Meluzínová Ivan Rektor Radomír Taláb Ralf Gold Hans‐Peter Hartung Attila Csányi László Csiba Gábor Jakab Rogier Q. Hintzen Chris H. Polman Wiesław Drozdowski Waldemar Fryze Jan Kochanowicz Hubert Kwieciński Zdzislaw Maciejek Sebastian Schimrigk Krzysztof Selmaj Andrzej Szczudlik A Wajgt Anna Belova A. Boiko Alexander Elchaninov Kozlov Va Odinak Mm С Б Шварков A A Skoromets I D Stolyarov O. V. Vorobieva И. А. Завалишин Jan Hillert Tomas Olsson Ludwig Kappos Mefküre Eraksoy Rana Karabudak Aksel Sıva Gavin Giovannoni Clive Hawkins Mohammed Sharief Basil Sharrack Christian Confavreux John E. Ware Michael Barnett Mark Paine Jeannette Lechner‐Scott Roy G. Beran Caron Chapman Raymond Schwartz Helmut Butzkueven Reynolds F Casse Richard Macdonell Thomas Berger Franz Fazekas Gerhard Ransmayr K. Vass Shibeshih Belachew Peter Paul De Deyn D. Decoo Bénédicte Dubois Robert Medaer Pierrette Seeldrayers Christian Sindic Luc Vande Gaer Ludo Vanopdenbosch Sanja Grgić Amit Bar‐Or Virender Bhan Jean‐Pierre Bouchard Suzanne Christie Pierre Grammond François Jacques Felix Veloso Galina Vorobeychik Vesna Brinar Vida Demarin Josip Rudež Silva Soldo-Butković Ranka Baraba Vurdelja Zdeněk Ambler David Doležil Eva Havrdová Petr Kaňovský Eva Meluzínová Jiří Nova'k Ivan Rektor Ondřej Škoda Marta Vachová Duchcovská William Camu Pierre Clavelou Antoanela

<h3>Abstract</h3> <h3>Background:</h3> Delayed-release dimethyl fumarate (DMF), indicated for the treatment of patients with relapsing-remitting multiple sclerosis (MS), is a disease-modifying therapy potential immunomodulatory and neuroprotective effects. In clinical trials, DMF was associated reduced white blood cell absolute lymphocyte counts. Current US prescribing information recommends obtaining complete count, including count (ALC), before initiating during treatment....

10.1212/cpj.0000000000000238 article EN cc-by-nc-nd Neurology Clinical Practice 2016-06-01

Objective: To validate kappa free light chain (KFLC) and lambda (LFLC) indices as a diagnostic biomarker in multiple sclerosis (MS). Methods: We performed multicenter study including 745 patients from 18 centers (219 controls 526 clinically isolated syndrome (CIS)/MS patients) with known oligoclonal IgG band (OCB) status. KFLC LFLC were measured paired cerebrospinal fluid (CSF) serum samples. Gaussian mixture modeling was used to define cut-off for indexes. Results: The the index 6.6 (95%...

10.1177/1352458519845844 article EN cc-by-nc Multiple Sclerosis Journal 2019-05-08

<h3>Background</h3> Twenty percent of familial amyotrophic lateral sclerosis (ALS) is caused by mutations in the superoxide dismutase 1 gene (<i>SOD1</i>). Few data exist on their clinicopathologic phenotypes. <h3>Objectives</h3> To determine clinical and pathologic phenotype associated with G93C mutation in<i>SOD1</i>and to compare survival ALS related this other subgroups. <h3>Design</h3> Retrospective study. <h3>Setting</h3> Tertiary referral center for neuromuscular disorders....

10.1001/archneur.63.2.262 article EN Archives of Neurology 2006-02-01

Multifocal visual evoked potential (MF-VEP) assesses a wider field than full-field VEP (FF-VEP) and potentially offers more precise analysis of optic nerve injury repair following neuritis. MF-VEP may offer advantages over FF-VEP as an endpoint in clinical trials remyelinating therapies. testing was used to study changes pathways 48% RENEW [phase II, opicinumab (anti-LINGO-1; BIIB033) vs. placebo after first acute unilateral neuritis] participants. This exploratory substudy compared mean...

10.1007/s40263-018-0575-8 article EN cc-by-nc CNS Drugs 2018-09-28

We evaluated the genetic impact of amyotrophic lateral sclerosis (ALS) risk gene never in mitosis a–related kinase 1 (NEK1) a Belgian cohort 278 patients with ALS (n = 245) or frontotemporal dementia (ALS-FTD, n 33) and 609 control individuals. identified 2 carrying loss-of-function (LOF) mutation, p.Leu854Tyrfs*2 p.Tyr871Valfs*17, that was absent group. A third LOF variant p.Ser1036* present sibs familial but also an unrelated person. Missense variants were common both (3.6%) controls...

10.1016/j.neurobiolaging.2017.08.021 article EN cc-by-nc-nd Neurobiology of Aging 2017-09-01

Background Cerebrospinal fluid (CSF) kappa free light chain (κFLC) measures gained increasing interest as diagnostic markers in multiple sclerosis (MS). However, the lack of studies comparing assay-dependent cutoff values hinders their use clinical practice. Additionally, optimal κFLC parameter for identifying MS remains a subject ongoing debate. Objectives The aim this study was to compare same-sample accuracies index, κIgG CSF κFLC/IgG ratio, and isolated (iCSF-κFLC) between two reference...

10.3389/fimmu.2024.1385231 article EN cc-by Frontiers in Immunology 2024-04-30

To explore differences in patient reported outcomes, health care resources and expenditures persons with multiple sclerosis (pwMS) or without access to an MS-nurse. An observational, multicenter cross-sectional study was conducted. Seven centers with, twelve MS-nurse participated. The impact scale-29 (MSIS-29) the primary outcome measure. Secondary measures included: hospital anxiety depression scale, coping measures, health-economic disease-knowledge parameters. Three hundred thirty-four...

10.1186/s12912-024-02682-6 article EN cc-by-nc-nd BMC Nursing 2025-01-27

Tick-borne encephalitis: prevention before the bite encephalitis is a viral infection transmitted through tick bites. Its incidence increasing in various parts of Europe. The initial clinical presentation can be mild. Headache and fever following travel to an endemic area are warning signs should prompt immediate referral emergency department. Without timely recognition, severe neurological complications may develop, necessitating intensive care. Fortunately, there effective safe vaccine...

10.47671/tvg.81.24.132 article EN Tijdschrift voor Geneeskunde 2025-05-22

The techniques currently used to detect a cerebrospinal fluid (CSF) leak are an indium radionucleotide scan and CT with intrathecal iodinated contrast agent. They have low spatial temporal resolution unpleasant for the patient. This open-label prospective observational cohort study was designed investigate feasibility, success ratio, complications therapeutic consequences of MRI gadolinium administered by lumbar puncture CSF leak.Patients were selected either confirmed liquorrhoea, recurrent...

10.1136/jnnp.2009.180752 article EN Journal of Neurology Neurosurgery & Psychiatry 2010-06-20

10.1016/j.jstrokecerebrovasdis.2017.05.015 article EN Journal of Stroke and Cerebrovascular Diseases 2017-06-13

The objective of this study was to evaluate prespecified and post hoc analyses in RENEW subgroups identify participants more likely benefit from opicinumab.RENEW assessed the efficacy/safety opicinumab versus placebo with a first unilateral acute optic neuritis (AON) episode. Difference visual evoked potential (VEP) latency affected eye at 24 weeks fellow baseline primary endpoint. Interactions between endpoint variables (including age, timing treatment initiation, impairment) using median...

10.1002/acn3.620 article EN cc-by-nc-nd Annals of Clinical and Translational Neurology 2018-08-15

We describe a 66-year-old woman who presented with dramatic course of PERM. Anti-glycine receptor antibodies were found. She stabilized after plasma-exchange and partly recovered. Eighteen months later, diagnosis smouldering breast cancer bone marrow metastasis was made. There are indications that this tumor already present at first presentation. An overview PERM anti-glycine is given.

10.1155/2013/589154 article EN cc-by Case Reports in Neurological Medicine 2013-01-01

Currently available disease-modifying treatments acting by modifying the immune response are ineffective in progressive multiple sclerosis (MS), which is caused a widespread axonal degeneration. Mechanisms suspected to be involved this degeneration reduced energy metabolism, glutamate toxicity, and cerebral blood flow. Fluoxetine might theoretically reduce MS because it stimulates metabolism through enhancing glycogenolysis, production of brain-derived neurotrophic factor, dilates...

10.1186/1745-6215-15-37 article EN cc-by Trials 2014-01-25
Coming Soon ...